A Proposed Protocol for the Investigation of the Safety and Efficacy of the COVID-19 Vaccine for Patients with Psychosis and Pilot Safety Findings from a Chinese Psychiatristâs Self-Experiment
*Corresponding Author:
Copyright: © 2021 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
We present a study protocol designed to test the safety and efficacy of the 2019 Coronavirus Disease (COVID-19) vaccine in
patients with major psychotic disease. A secondary objective is to investigate optional vaccination methods for these patients. In a selfexperiment,
a Chinese psychiatrist examined the safety and efficacy of the COVID-19 vaccine under clinical use of typical antipsychotic
agents and sedatives (olanzapine, duloxetine, and diazepam). For patients with extremely drug-resistant conditions, the safety of the
COVID-19 vaccine under electroconvulsive therapy was also investigated. The entire study process was recorded on high-definition
video. This clinical study protocol is, to our knowledge, the first of its kind. Our findings will shed new light on the protection of patients
with psychotic diseases from COVID-19 infection.